Corcept Therapeutics   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Menlo Park CA United States (1998)
Status: No NME R&D (1998)

Organization Overview

First Clinical Trial
2003
NCT00105105
First Marketed Drug
2012
mifepristone (mifeprex)
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

CORCEPT THERAP | Corcept Therapeutics | Corcept Therapeutics, Menlo Park, CA 94025

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

ACTH-Secreting Pituitary Adenoma (Phase 3)

Adenocarcinoma (Phase 3)

Adenoma (Phase 3)

Adrenal Insufficiency (Phase 2)

Adrenocortical Adenoma (Phase 3)

Adrenocortical Carcinoma (Phase 1)

Adrenocortical Hyperfunction (Phase 3)

Alzheimer Disease (Phase 2)

Body Weight (Phase 2)

Breast Neoplasms (Phase 1)

Carcinoma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 1)

Carcinoma, Transitional Cell (Phase 1)

Cushing Syndrome (Phase 3)

Depression (Phase 3)

Depressive Disorder (Phase 3)

Depressive Disorder, Major (Phase 3)

Disease (Phase 3)

Fatty Liver (Phase 2)

Lung Neoplasms (Phase 2)

Mental Disorders (Phase 3)

Neoplasms (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 2)

Ovarian Neoplasms (Phase 2)

Pituitary ACTH Hypersecretion (Phase 3)

Prostatic Neoplasms (Phase 2)

Psychotic Disorders (Phase 3)

Sarcoma (Phase 1)

Schizophrenia (Phase 2)

Signs and Symptoms (Phase 3)

Syndrome (Phase 3)

Triple Negative Breast Neoplasms (Phase 1)

Weight Gain (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 64
  • # of Trial APIs: 26